for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eidos Therapeutics Inc

EIDX.OQ

Latest Trade

128.44USD

Change

5.91(+4.82%)

Volume

30,997

Today's Range

119.74

 - 

128.61

52 Week Range

28.39

 - 

132.54

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
122.53
Open
120.92
Volume
30,997
3M AVG Volume
3.03
Today's High
128.61
Today's Low
119.74
52 Week High
132.54
52 Week Low
28.39
Shares Out (MIL)
38.87
Market Cap (MIL)
4,763.10
Forward P/E
-41.63
Dividend (Yield %)
--

Next Event

Q4 2020 Eidos Therapeutics Inc Earnings Release

Latest Developments

More

BridgeBio Pharma And Eidos Therapeutics Approve Co's Acquisition Of Eidos Therapeutics

Eidos Therapeutics Posts Q3 Loss Per Share $0.79

Eidos Therapeutics Reports Second Quarter Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eidos Therapeutics Inc

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.

Industry

Biotechnology & Drugs

Contact Info

101 Montgomery St Ste 2550

SAN FRANCISCO, CA

94104-4158

United States

+1.650.3919740

http://eidostx.com

Executive Leadership

Jonathan C. Fox

President, Chief Medical Officer

Neil Kumar

Chief Executive Officer, Director

Uma Sinha

Chief Scientific Officer, Director

Cameron Turtle

Chief Business Officer

Suzanne Sawochka Hooper

Independent Director

Key Stats

3.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-1.860

2019

-1.030

2020(E)

-2.944
Price To Earnings (TTM)
--
Price To Sales (TTM)
37,504.69
Price To Book (MRQ)
38.49
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.62
LT Debt To Equity (MRQ)
13.62
Return on Investment (TTM)
-63.75
Return on Equity (TTM)
-59.27

Latest News

Latest News

BRIEF-Eidos Therapeutics Reports Q1 Loss Per Share Of $0.60

* EIDOS THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE

BRIEF-Eidos Therapeutics - In Light Of Covid-19, Experiencing Delays In Or Temporary Suspension Of Enrollment Of Patients In Ongoing Clinical Trials

* EIDOS THERAPEUTICS - IN LIGHT OF COVID-19, EXPERIENCING DELAYS IN OR TEMPORARY SUSPENSION OF ENROLLMENT OF PATIENTS IN ONGOING CLINICAL TRIALS

BRIEF-Eidos Therapeutics Reports Fourth-Quarter Results

* EIDOS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS AND BUSINESS UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up